ResMed Inc. (RMD), the San Diego-based leader in sleep apnea and respiratory care devices, has spent much of the past year trading well below the lofty levels it touched during its 52-week run. With shares recently changing hands around $231, investors are increasingly asking a straightforward question: can RMD climb back toward the $300 mark, a level it approached but never decisively cleared? The answer depends on a mix of product momentum, margin expansion, and how the market resolves two long-running competitive concerns.
ResMed's shares traded as high as approximately $285 during the past year before pulling back, so the round-number $300 target represents both a natural psychological barrier and the logical next step beyond the stock's prior peak. It is not an arbitrary figure: several sell-side firms have carried price objectives at or above $300 at various points, and the level sits within the range of the broader Wall Street consensus, which extends from a low of $175 to a high of roughly $320. That places $300 firmly in the "challenging but not unrealistic" zone for the current market outlook.
ResMed is one of the world's largest providers of continuous positive airway pressure (CPAP) devices, masks, and connected software used to treat obstructive sleep apnea (OSA). The company generates roughly two-thirds of its revenue in the Americas, with the balance spread across Europe, Asia-Pacific, and other regions. In fiscal 2026, net revenue rose about 10% to approximately $5.65 billion, while gross margin improved to 61.1% from 59.4% a year earlier. The business carries a market capitalization near $33 billion, a price-to-earnings (P/E) ratio around 22, and a modest dividend yield of roughly 1.1%.
ResMed's strongest argument for approaching $300 rests on a new product cycle and steady margin gains. The company's AirSense 11 platform and newer mask lines such as the AirTouch franchise have supported share gains and improved patient compliance, which in turn feeds the high-margin resupply business. Management has also signaled a path toward further gross margin expansion, targeting gradual annual accretion through the end of the decade. Recent strategic moves, including the acquisition of VirtuOx in home diagnostic testing and Noctrix Health in restless legs syndrome, as well as a partnership with OURA, reinforce a broader push into digital and connected health. A planned sale of the MatrixCare software business for $490 million also reflects a sharper focus on core respiratory markets.
The most persistent overhang is the rise of GLP-1 weight-loss medications. Because obesity is a leading contributor to sleep apnea, investors have worried that drugs such as those from Eli Lilly could reduce the long-term need for CPAP therapy. The approval of a GLP-1 treatment specifically for OSA has amplified that concern. ResMed has argued—and some third-party data suggests—that new patient referrals into the sleep diagnostic funnel remain robust, but the thesis continues to weigh on sentiment. A second challenge is the anticipated re-entry of Philips Respironics into the U.S. market after years of recall-related remediation, which could reintroduce competitive pressure in devices.
Wall Street remains broadly constructive on ResMed, with a consensus rating of Buy and an average one-year price target in the mid-$240s—only modestly above the current share price. The dispersion is notable, however: recent targets range from around $175 to as high as $320, and several firms, including UBS, have maintained objectives at or near $300 at various points. That wide spread reflects genuine disagreement over the durability of the GLP-1 threat and the pace of margin improvement. A stock trading at roughly 22 times trailing earnings leaves little room for disappointment if growth decelerates.
From a technical analysis perspective, $300 is a clear psychological resistance level that also coincides with the upper boundary of prior analyst targets. Below it, the stock faces resistance in the mid-to-upper $280s, where it previously stalled. On the downside, support is likely to be found near $230, a level that has acted as both support and resistance in recent trading, with the lower portion of the 52-week range near $180 representing a more substantial floor. A decisive break above the prior peak would be a meaningful signal that the path toward $300 is opening, while a failure to hold current support could defer that outcome.
For traders monitoring whether ResMed can sustain an advance toward $300, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to track shifting conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to uncover new opportunities, monitor existing positions, and identify changing market trends more efficiently. As the technical picture around RMD evolves, these AI-generated signals can help investors stay aligned with the prevailing trend.
A move to $300 for ResMed is realistic but not imminent. The strongest supporting factors are a genuine new product cycle, recurring mask revenue, expanding margins, and a structurally growing market for sleep apnea treatment. The primary obstacles are the unresolved GLP-1 question, potential competitive pressure from Philips Respironics, and a valuation that already embeds meaningful growth expectations. Investors should monitor device and mask growth rates, gross margin trajectory, and any data clarifying the impact of weight-loss drugs on new patient flow. A sustained break above the prior highs would materially improve the odds that the $300 milestone comes into reach, but the path there is more likely to unfold over several quarters than in a single surge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with COO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -3.20% | ||
| COO - RMD | 48% Loosely correlated | -2.73% | ||
| BAX - RMD | 48% Loosely correlated | -3.76% | ||
| BDX - RMD | 46% Loosely correlated | -3.05% | ||
| SOLV - RMD | 44% Loosely correlated | -1.72% | ||
| ISRG - RMD | 42% Loosely correlated | -4.51% | ||
More | ||||
| Ticker / NAME | Correlation To RMD | 1D Price Change % |
|---|---|---|
| RMD | 100% | -3.20% |
| Pharmaceuticals: Other industry (50 stocks) | 39% Loosely correlated | -0.73% |
| Pharmaceuticals industry (155 stocks) | 0% Poorly correlated | -1.08% |